Satellos Bioscience Inc.

TSX:MSCL Stock Report

Market Cap: CA$96.7m

Satellos Bioscience Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSX:MSCL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Oct 24BuyCA$9,863Michael RudnickiIndividual13,698CA$0.72
09 Oct 24BuyCA$427,500Franklin BergerIndividual750,000CA$0.57
18 Sep 24BuyCA$2,054Michael CrossIndividual4,255CA$0.48
16 May 24BuyCA$9,300Elizabeth WilliamsIndividual20,000CA$0.47
16 May 24BuyCA$13,605Francis GleesonIndividual29,000CA$0.47
02 May 24BuyCA$20,422Francis GleesonIndividual47,000CA$0.43
12 Feb 24SellCA$351,960Bloom Burton Investment Group Inc.Company700,000CA$0.50
07 Feb 24BuyCA$18,127Geoff MacKayIndividual33,000CA$0.57
02 Feb 24BuyCA$27,670Geoff MacKayIndividual53,000CA$0.54
26 Jan 24BuyCA$48,800Geoff MacKayIndividual98,000CA$0.54
24 Jan 24BuyCA$399,880Brian BloomIndividual769,000CA$0.52
24 Jan 24SellCA$399,880Bloom Burton Investment Group Inc.Company769,000CA$0.52

Insider Trading Volume

Insider Buying: MSCL insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MSCL?
Owner TypeNumber of SharesOwnership Percentage
VC/PE Firms7,229,7586.35%
Individual Insiders18,067,16815.9%
General Public88,520,88877.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 11 shareholders own 22.23% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.64%
Franklin Berger
7,559,000CA$6.4m11%no data
6.35%
Bloom Burton Investment Group Inc.
7,229,758CA$6.1m2.97%51.0%
3.35%
Francis Gleeson
3,816,389CA$3.2m0%no data
2.72%
Michael Rudnicki
3,097,918CA$2.6m0.44%no data
1.5%
William Jarosz
1,711,374CA$1.5m0%no data
1.3%
Brian Bloom
1,478,810CA$1.3m0%no data
0.22%
Geoff MacKay
254,422CA$216.3k0%no data
0.07%
J. Hall
80,000CA$68.0k0%no data
0.035%
Elizabeth Williams
40,000CA$34.0k0%no data
0.022%
William McVicar
25,000CA$21.2k0%no data
0.0037%
Michael Cross
4,255CA$3.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:03
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Satellos Bioscience Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthCanaccord Genuity
Yu HeH.C. Wainwright & Co.
David BautzZacks Small-Cap Research